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ABStrACt 
Introduction: Indirect immunofluorescence on HEp-2 cells is considered the gold standard for the detection of autoantibodies against 
cellular antigens. However, the culture conditions, cell fixation and permeabilization processes interfere directly in the preservation and 
spatial distribution of antigens. Therefore, one can assume that certain peculiarities in the processing of cellular substrate may affect 
the recognition of indirect immunofluorescence patterns associated with several autoantibodies. Objective: To evaluate a panel of serum 
samples representing nuclear, nucleolar, cytoplasmic, mitotic apparatus, and chromosome plate patterns on HEp-2 cell substrates from 
different suppliers. Materials and methods: Seven blinded observers, independent from the three selected reference centers, evaluated 17 
samples yielding different nuclear, nucleolar, cytoplasmic and mitotic apparatus patterns on HEp-2 cell slides from eight different brands. 
The slides were coded to maintain confidentiality of both brands and participating centers. Results: The 17 HEp-2 cell patterns were 
identified on most substrates. Nonetheless, some slides showed deficit in the expression of several patterns: nuclear coarse speckled/U1-
ribonucleoprotein associated with antibodies against RNP (U1RNP), centromeric protein F (CENP-F), proliferating cell nuclear antigen 
(PCNA), cytoplasmic fine speckled associated with anti-Jo-1 antibodies (histidyl synthetase), nuclear mitotic apparatus protein 1 (NuMA-1) 
and nuclear mitotic apparatus protein 2 (NuMA-2). Conclusion: Despite the overall good quality of the assessed HEp-2 substrates, there 
was considerable inconsistency in results among different commercial substrates. The variations may be due to the evaluated batches, 
hence generalizations cannot be made as to the respective brands. It is recommended that each new batch or new brand be tested with a 
panel of reference sera representing the various patterns.
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introDuCtion
The screening of autoantibodies against cellular antigens, 
antinuclear antibodies (ANA), is a test developed to aid in the 
diagnosis of patients with suspected autoimmune diseases. It 
is performed through indirect immunofluorescence (IIF) on 
tumor cells derived from human larynx carcinoma (HEp-2 – 
American Type Culture Collection [ATCC] CCL-23), a continuous 
tumor cell lineage, hence its designation (ANA-HEp-2). It has 
fully replaced the use of animal tissue as antigen substrate due 
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to multiple factors, among which stands out the possibility of a 
myriad of human autoantigens in a wide spatial arrangement 
and enriched by the representation of various cell cycle stages. 
These characteristics allow an excellent visualization of the spatial 
distribution of autoantigens, resulting in the identification of 
multiple IIF patterns. The representation of cells at different stages 
of cell division promotes detection of autoantibodies against a 
wide variety of autoantigens expressed in mitosis and interphase 
(phases G0, G1, G2 and S). Moreover, they feature multiple nucleoli 
and cytoplasm rich in organelles and cytoplasmic proteins(3, 5). Due 
to these characteristics, autoantibody screening against cellular 
components through IIF using HEp-2 cells as antigen substrate 
is currently recommended as the gold standard by the American 
College of Rheumatology(13).
One of the benefits of ANA-HEp-2 method also comprises a 
hindrance in this test, that is to say that its extreme sensitivity 
leads to positive results in some individuals without evidence of 
systemic autoimmune disease. In fact, national and international 
studies estimate a frequency of approximately 13% positive results 
and titer of 1/80 in the general population(11, 17). This scenario 
becomes even more problematic in view of the widespread use of 
this test. Previously, antinuclear antibody screening was requested 
mostly by nephrologists and rheumatologists, specialists who 
commonly treat patients with systemic lupus erythematosus 
(SLE), systemic sclerosis and other systemic autoimmune diseases. 
Currently, many experts such as dermatologists, gastroenterologists, 
gynecologists, orthopedic surgeons, otolaryngologists, neurologists 
and psychiatrists have included it in their laboratory screenings. 
Considering the fact that a minority of patients assisted at these 
clinics will develop systemic autoimmune disease, there is a 
scenario of low pre-test probability for these syndromes. The 
result is a high frequency of positive results in unexpected clinical 
settings, affecting the positive predictive value of ANA-HEp-2. 
Accordingly, it is important to highlight that the yielded results 
should be considered and interpreted cautiously.
One of the ways that may assist in the correct interpretation 
of a positive ANA-HEp-2 result is the careful analysis of IIF 
pattern. In fact, in recent years the relevance of IIF on ANA-HEp-2 
interpretation has been consistently emphasized(11). The observed 
pattern may provide preliminary information on the nature 
of the autoantibody in a given sample and even indicate which 
additional and specific tests should be conducted. Some examples 
are the following: nuclear speckled pattern, which suggests the 
presence of anti-Sm and/or anti-U1RNP(14); nucleolar pattern 
with perichromosome plate, which indicates anti fibrillarin 
antibodies(12); cytoplasmic dense fine speckled pattern, often 
associated with the presence of ribosomal P protein antibodies(9); 
centromeric nuclear pattern, which results from the identification 
of centromere proteins (CENPs)(6); nuclear type and fine speckled 
nucleolar with cytoplasmic staining and presence of fluorescent 
spots on the chromosome plate (mixed pattern), which is strongly 
associated with the presence of deoxyribonucleic acid (DNA) 
topoisomerase 1 antibodies(4).
Successive methodological improvements, namely the 
quality of secondary antibody and overall microscope resolution, 
have resulted in a significant increase in assay sensitivity, hence 
unexpected positive results have commonly been observed(11, 17). 
Furthermore, several companies have started to produce 
commercial kits for ANA-HEp-2, resulting in its widespread use 
worldwide(7). However, cell culture conditions and slide preparation 
are restricted to protocols adapted by manufacturers and whose 
technical features sometimes are not shared with users. This is 
relevant, since the availability of epitopes and spatial distribution 
of autoantigens may undergo considerable changes as a result of 
culture conditions and cell fixation. Consequently, the same serum 
in slides from different suppliers may result in distinctive IIF 
patterns due to differences in the expression of nuclear, nucleolar, 
cytoplasmic autoantigens and chromosome plate (Figure 1).
Given the relevance of IIF pattern characterization and 
classification and the fact that the manufacturing process of HEp-2 
cells slides have potential influence on antigen distribution and 
epitope availability, it is vital to identify how sensitive the various 
IIF patterns are in relation to specific preparations of antigenic 
substrate. Therefore, the objective of this study was to evaluate a 
panel of IIF patterns on HEp-2 cells from different origins.
MAtEriALS AnD MEthoDS
Serum samples
A panel of human serum samples (Table 1) was selected 
from the autoantibody serum bank at Fleury Medicina e Saúde 
– Research and Development Department (R&D) to represent the 
most relevant IIF patterns on HEp-2 and also acknowledged by the 
Brazilian Consensus for autoantibodies on HEp-2(2). The samples 
were sequentially numbered so that it was not possible to identify 
its immunological specificity (Table 2). Accordingly, all readings 
were conducted blindly. The samples were kept in a freezer (-80ºC) 
until test performance. A complete set of this sample panel was 
distributed to seven independent observers from three centers of 
excellence in autoantibodies: Pontifícia Universidade Católica 
Clinical Laboratory (PUC-Goiás), Hospital Albert Einstein 
Immunology Laboratory and Group Fleury, Immunology and 
R&D Departments. To ensure data confidentiality, the three centers 
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tABLE 1 – Description of ANA-HEp-2 patterns  
distributed to the participating centers
IIF pattern Abbreviation
Nuclear patterns
Homogeneous speckled Ho
Coarse speckled CS
Coarse speckled type reticulated CSTR
Dense fine speckled DFS
Quasi-homogeneous QH
Centromeric C
Fine speckled and mitotic apparatus NuMA-1
Fine speckled and rare nuclear dots FS RND
Multiple nuclear dots MND
PCNA PCNA
CENP-F CENP-F
Nucleolar patterns
Homogeneous nucleolar HoNu
Nucleolar clumpy NuP
Fine speckled + nucleolar speckled + NOR RNA pol
Cytoplasmic patterns
Fine speckled Cyto FS
Dense fine speckled Ctto DFS
Metaphase chromosome plate
Mitotic spindles NuMA-2
ANA-HEp-2: antinuclear antibodies HEp-2; IIF: indirect immunofluorescence; 
PCNA: proliferating cell nuclear antigen; CENP-F: centromeric protein F; 
NOR: nucleolar organizing region; RNA: ribonucleic acid.
figurE 1 –  IIF on HEp-2 cells
A-C: serum sample from patient with scleroderma and with nucleolar pattern (titer ≥ 
1/640) processed on three substrates from different commercial brands; D-E: serum sample 
from patient with anti-U1 RNP antibodies and anti-actin processed on substrates from two 
different suppliers. 
IIF: indirect immunofluorescence; RNP: ribonucleoprotein.
were randomly designated as centers A, B and C. The readings in 
each center were harmonized, creating a single consolidated 
report.
Antigenic substrate – Hep-2 cells
The study included seven brands of commercial kits for 
HEp-2 autoantibodies, which met basic quality criteria as to 
cell density, number of mitosis per field, cell morphology and 
quality of the conjugates. Furthermore, they were in accordance 
with the sale regulations proposed by the National Agency 
of Sanitary Surveillance (ANVISA). All commercial kits were 
kindly provided by the suppliers named herein in alphabetical 
order: (1) Bion Interpreise, Inc. (batch NA-3642 - Reference AN 
- 1012); (2) Medizinische Euroimmun Labordiagnostika AG 
(batch F090806D6 - Code FA 1520-0405); (3) Hemagen Diagnostic 
Inc. (Virgo batch 4149 - code 902345); (4) IMMCO Diagnostics 
(batch 905 197 - code 1102-60); (5) Immunoconcepts HEp2000 
ANA-Ro Test System (batch 0820403 - reference AS 2014 -Ro); (6) 
Inova Diagnostics, Inc. (batch 870 364 - code 708100); and (7) 
Viro-Immun Labor-Diagnostika GmbH (batch AHEPK 06d-09 - 
reference IFG109). They were carefully identified with numerals 
in order to maintain confidentiality. Moreover, we counted eight 
HEp-2 slides prepared at UNIFESP Immuno-Rheumatology 
Laboratory (Universidade Federal de São Paulo-Escola Paulista 
de Medicina [UNIFESP-EPM]). For the preparation of these 
slides, HEp-2 cells were cultured in Dulbecco modified eagle’s 
medium (DMEM) with 10% fetal bovine serum (Gibco Invitrogen 
Life Technologies) and incubated at 5% CO
2
 and 37ºC until they 
became subconfluent. Subsequently, the cells were trypsinized 
and reseeded directly on glass slides with circles delimited by 
hydrophobic mask. After 24 hours of growth under the same 
conditions, the culture medium was withdrawn and the slides 
washed in PBS (Phosphate Buffered Saline - sodium phosphate 
10 mmol/1, NaCl, 0.15 mol/l, pH 7.2 to 7.4). After removing excess 
PBS, the cells were immediately fixed in methanol at -20ºC for 8 
minutes and permeabilized in acetone at -20ºC for 2 minutes. After 
drying at room temperature, the slides were wrapped in aluminum 
foil and cling film and stored at -70ºC until use.
Each central processor received the serum samples and 
ANA-HEp-2 mini-kits from each of the suppliers mentioned 
above, including conjugates and appropriate solutions. The 
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centers were advised to strictly follow the technical procedures 
for performing IIF in accordance with the technical instructions 
from each manufacturer. They were also instructed to avoid visual 
identification under microscope analysis. 
IIF on in house slides
For the reaction of IFI with the substrate prepared by 
UNIFESP-EPM Immuno-Rheumatology Department, 20 μl of 
serum were diluted at 1/80 PBS. Slides with HEp-2 cells were 
incubated for 30 ± 5 minutes in a humid chamber at 37ºC. 
Subsequently, two 10-minute washes were performed with PBS. 
The fluorescent conjugate contained sheep immunoglobulins 
against human immunoglobulin class G (IgG) stained 
with fluorescein isothiocyanate (fluorescein isothiocyanate 
conjugate [FITC] - Fluoline® G bioMérieux SA, Code 75692, 
Marcy l’Etoile, France) and diluted in Evans blue solution 
(10 mg Evans Blue in 100 ml PBS) at 1/200. This conjugate 
was applied into each well and incubated for 30 ± 5 minutes in 
tABLE 2 – Interpretation results of IIF patterns on ANA-HEp-2 from each participating center
Antibody patterns on ANA-HEp-2 Commercial substrates1
1 2 3 4 5 6 7 8
Ho +++2 +++ +++ +++ +++ +++ +++ +++
CS +++ +++ +++ +++ +++ +++ +++ ΘΘΘ
CSTR +++ +++ +++ +++ +++ +++ +++ +++
DFS +++ +++ +++ +++ +++ +++ +++ +++
QH ++Θ ++Θ ++Θ ++Θ ++Θ ++Θ ++Θ ++Θ
C +++ +++ +++ +++ +++ +++ +++ +++
NuMA-1 ++Θ ++Θ ++Θ ++Θ ++Θ ++Θ ++Θ ΘΘΘ
FS RND +++ +++ +++ +++ +++ +++ ΘΘΘ +++
MND ++Θ ++o +++ +++ +++ +++ +++ +++
PCNA +++ ΘΘΘ ΘΘΘ +++ ΘΘΘ ΘΘΘ ΘΘΘ ΘΘΘ
CENP-F ++Θ ΘΘΘ ΘΘΘ ΘΘΘ ΘΘΘ ΘΘΘ ++o ΘΘΘ
HoNu +++ +++ +++ +++ +++ +++ +++ +++
NuP +++ +++ +++ +++ +++ +++ +++ +++
RNA pol +++ +++ +++ +++ +++ +++ +++ +++
Cyto FS +++ ΘΘΘ ΘΘΘ ΘΘΘ ΘΘΘ +++ ΘΘΘ ΘΘΘ
Cyto DFS ++Θ ++Θ ++o ++o ++o ++o ++o ++o
NuMA-2 +++ +++ +++ +++ +++ +++ +++ ΘΘΘ
Ho: homogeneous speckled; CS: coarse speckled; CSTR: coarse speckled type reticulated; DFS: dense fine speckled; QH: quasi-homogeneous; C: centromeric; NuMA-1: 
fine speckled and mitotic apparatus; FS RND: fine speckled and rare nuclear dots; MND: multiple nuclear dots; PCNA: proliferating cell nuclear antigen; CENP-F: 
centromeric protein F; HoNu: homogenous nucleolar; NuP: nucleolar clumpy; RNA pol: fine speckled + nucleolar speckled + NOR; Cyto FS: fine speckled; Cyto DFS: 
dense fine speckled; NuMA-2: mitotic spindles; NOR: nucleolar organizing region. 
1: numbers 1 to 8 represent the different substrate brands included in this study; 2: symbols + and Θ indicate the centers that identified or not, respectively, the 
different patterns on the surveyed substrates. 
a humid chamber at 37ºC. This was followed by two 10-minute 
wash cycles with PBS and microscope slide mounting with 70% 
PBS glycerol and coverslip. IIF reaction on commercial slides 
was performed in strict accordance with the recommendations 
of each supplier.
All slide readings were conducted blindly so that the examiner 
was unaware of the sample origin and slide manufacturer. The 
three centers employed epifluorescence microscope with mercury 
lamp and there were the following specific features in each center: 
center A used an Olympus BX-50 fluorescence microscope with 
Ushio mercury lamp under 400× magnification; center B used 
a Leica DMLB fluorescence microscope with a 100 watt mercury 
vapor lamp under 1,000× magnification; center C used a Nikon 
Eclipse E600W microscope with HBO mercury lamp under 400× 
magnification.
The images were captured by an Olympus QColor 3 camera 
using QCapture program. Image-J and Image-Pro Plus 5.1 
programs were applied for image analysis. 
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Strategy for evaluating results
The readings were recorded individually in standardized 
forms and sent to the coordinating center for data compilation in 
a central spreadsheet, which included concordance formulas for 
result assessment. For this analysis, it was deemed that the purpose 
of this study was to determine the degree of reproducibility of 
different patterns in different commercial substrates and through 
readings conducted by different specialists. Since the actual ANA-
HEp-2 test reading contains a considerable degree of subjectivity, 
we considered reproducible those patterns that were identified by 
at least two participating centers (Figure 2).
 
figurE 2 –  Characterization ability of 17 autoantibody patterns on HEp-2 cells by eight 
different slides (seven commercial and one in house)
The grey columns indicate the reading concordance within different slides and the black 
columns suggest inability to identify them.
*QH nuclear quasi-homogeneous speckled pattern: center C identified the pattern as dense 
fine speckled on the first five slides and as homogeneous nuclear in the last three slides.
Ho: homogeneous speckled; DFS: dense fine speckled; QH: quasi-homogeneous speckled*; 
CSTR: coarse speckled type reticulated; C: centromeric; MND: multiple nuclear dots; FS RND: 
fine speckled and rare nuclear dots; CS: coarse speckled; CENP-F: centromeric protein F; 
PCNA: proliferating cell nuclear antigen; Cyto FS: fine speckled; Cyto DFS: dense fine speckled; 
Nu Ho: nucleolar homogeneous; Nu P: nucleolar clumpy; RNA pol: fine speckled + nucleolar 
speckled + nucleolar organizing region; NuMA-1: fine speckled and mitotic apparatus; 
NuMA-2: mitotic spindles.
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Seventeen IIF patterns were properly identified by the readers 
from the three centers in most commercial HEp-2 cell substrates. 
For data compilation, the reading was considered consistent 
when two out of three participating centers reported the same 
result (Figure 2). In general, eight tested substrates showed 
good reproducibility of all seventeen IIF patterns. However, 
some patterns exhibited some variability in some substrate 
identifications (Figure 2). The nuclear patterns that were 
reproduced in the eight assessed brands of HEp-2 slides were the 
following: homogeneous (sample with anti-native DNA), dense 
fine speckled (sample with anti-LEDGF/p75 antibodies [lens 
epithelium-derived growth factor]), quasi-homogeneous, coarse 
speckled type reticulated, centromeric, and multiple nuclear dots 
(sample with anti-Sp-100). 
The nuclear fine speckled and the rare nuclear dot patterns 
were reproduced in 7/8 (87.5%) slide brands. In slide G, it was 
possible to observe only the nuclear fine speckled pattern. To 
view the nuclear coarse speckled pattern, we used a sample with 
anti-U1 RNP autoantibodies (ribonucleoprotein U1). Slide H 
showed nuclear fine speckled pattern with a slight difference in 
intensity among nuclei from cells in interphase. It was possible to 
identify the coarse speckled pattern (Figure 3) in the remaining 
slides. The nuclear pattern associated with antibodies against 
CENP-F (centromeric protein F) was identified only in slides A 
and G, whereas the nuclear fine speckled pattern was observed 
in the others (Figure 4). The nuclear pattern associated with 
antibodies against PCNA was observed only in slides A and D, 
whereas the nuclear fine speckled pattern was identified in the 
others (Figure 5).
figurE 3 –  Nuclear coarse speckled pattern in samples with anti-U1 RNP antibodies
Upper panel: expected and observed pattern on slides A-G. 
Lower panel: discrepant fine speckled pattern observed on slide H.
RNP: ribonucleoprotein.
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figurE 4 –  CENP-F pattern
Upper panel: expected and observed pattern on slides A and G; arrow a: cell in 
prophase expressing centromeres; arrow b: furrowed chromosome plate; arrow c: cell 
nuclei with subtle difference in fluorescence intensity; arrow d: intercellular bridge.
Lower panel: discrepant nuclear fine speckled observed in slides B, C, D, E, F 
and H.
CENP-F: centromeric protein F.
figurE 5 –  PCNA pattern
Upper panel: expected and observed pattern in slides A and D. The arrows indicate 
characteristic pleomorphism of the visualized pattern when there is presence of 
antibodies against cell proliferation antigen. 
Lower panel: discrepant nuclear fine speckled observed in slides B, C, E, F, G and H.
PCNA: proliferating cell nuclear antigen.
To evaluate the reproducibility of cytoplasmic patterns, we used a 
sample with anti-Jo-1 autoantibodies, which can be visualized as a fine 
speckled pattern, and a sample with autoantibodies against ribosomal 
P protein, which can be visualized as dense fine speckled pattern. The 
cytoplasmic fine speckled pattern was observed only in slides A and 
F, whereas slides C, G and H exhibited nuclear fine speckled pattern. 
There was a negative reaction in slides B, D and E. The cytoplasmic 
dense fine speckled pattern was observed in all slides.
To assess the reproducibility of nucleolar patterns, we applied 
the following protocol: a sample with anti-PMScl autoantibodies, 
which could be visualized as nuclear fine speckled and 
homogeneous nucleolar patterns; a sample with anti-fibrillarin 
autoantibodies, which could be identified as nucleolar clumpy 
pattern; a sample with a pattern suggestive of the presence of anti-
RNA polymerase 1. Nucleolar patterns were recognized in all slides.
NuMA and NuMA-1-2 patterns, associated with the mitotic 
apparatus, were not detected in any of the slides. In slide H, 
NuMA-1 was observed only as a speckled nuclear pattern and 
NuMA-2 presented weak reaction and low definition (Figure 6A 
and B).
DiSCuSSion
IIF test with HEp-2 cells as antigen substrate is currently 
the gold standard for the detection of autoantibodies against 
cellular antigens (ANA-HEp2)(21). The yielded results indicate the 
relative serum levels (titer) and probable antigenic associations 
(immunofluorescence pattern) of autoantibodies present in the 
sample(10, 11 ). Thus, the test valuation and interpretation were 
based on the previous information. For example, the homogeneous 
nuclear pattern suggests the presence of autoantibodies against 
native DNA and/or nucleosome, which are considered SLE 
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different immunofluorescence patterns in different slide brands 
(Figures 3 to 6), which may result in differences in results between 
laboratories and ultimate clinical consequences.
Some inconsistent results between slides corroborate the 
literature, insofar as some target antigens are more susceptible 
to damages resulting from the fixation protocols and cell culture 
handling(8, 18, 20). The cytoplasmic speckled pattern associated 
with anti-Jo-1, for example, is not always observed, and this is an 
anticipated fact, because the target antigen of these autoantibodies 
is not always preserved in this type of substrate. The appropriate 
indication of antibody presence has direct clinical application due 
to the fact that it is a myositis marker. Therefore, whenever there 
is clinical suspicion of its presence, specific tests such as double 
immunodiffusion are recommended, given the unreliability 
of ANA-HEp-2 test in this case. The same is expected in the 
identification of PCNA pattern as the target antigen is extremely 
sensitive to handling. It is also known that SS-A/Ro antigen may 
not be present in some HEp-2 cell preparations.
According to the literature, except for these fragile antigens, 
the concordance observed among the evaluated substrates was 
unexpected. The present study showed a favorable scenario in 
which most patterns were suitably detected in most antigenic 
substrates. This result is possibly related to the fact that the 
samples were selected because of their unique IIF patterns in 
representative medium/high titers. It is reasonable to assume 
that reproducibility may be lower when test samples are 
associated with less clear and mixed patterns. Nevertheless, it is 
worth highlighting that we observed inaccurate identification 
of some patterns in some substrates. For example, the nuclear 
speckled pattern resulting from the presence of autoantibodies 
against U1RNP was not identified in slide H. The same result was 
observed in patterns associated with mitotic spindle components 
(NuMA-1 and NuMA-2). This demonstrates the paramount need 
to use a panel of control samples for the validation of batches and 
HEp-2 cell brands used in ANA-HEp-2 tests. It is particularly worth 
mentioning that laboratories require more than one commercial 
substrate for occasional result confirmation (Figure 1). In 
addition, they need to maintain collections of positive samples 
that allow to assess continually the reproducibility of different kits 
in the identification of various patterns.
The differences among the participants’ interpretations 
reveal the need for continued education and training in order 
to ensure the appropriate identification of the surveyed patterns 
(Figure 2). Thus, it is important to highlight the major role of 
different groups worldwide attempting to standardize ANA-HEp-2 
test. Brazil is a pioneer in this initiative with the establishment 
of the National Consensus for autoantibody research on 
figurE 6 –  NuMA-1 and NuMA-2 patterns
Upper panel: expected NuMA-2 observed in slides A to G.
Lower panel:  expected NuMA-2 pattern identified in slides A to G.
NuMA-1; nuclear mitotic apparatus protein 1; NuMA-2: nuclear mitotic 
apparatus protein 2. 
markers(19), whereas the dense fine speckled pattern demonstrates 
the presence of anti-LEDGF/p75 antibodies, which have no specific 
relation with systemic autoimmune disease and are commonly 
found in healthy individuals(11). The same considerations apply 
to other standards: nuclear speckled, commonly associated with 
the presence of anti-Sm, which is a SLE marker(15); anti-U1 RNP, 
which is found in SLE, mixed connective tissue disease and 
systemic sclerosis; coarse speckled type reticulated associated 
with small ribonucleoproteins and even in high titers is rarely 
associated with a specific autoimmune disease(11).
Accordingly, different commercial brands of HEp-2 slides 
may have impact on the accurate identification of IIF pattern 
in ANA-2-HEp-2 assay, from which practical implications arise, 
inasmuch as the inaccuracy of a given antigen expression may 
lead to misinterpretations (Figure 1). Considering that the 
expression and topographical distribution of autoantigens is 
under direct influence of HEp-2 fixation method, it is possible 
that some IIF patterns are not adequately expressed due to the 
way that the antigenic substrate(18, 20) was prepared. The diversity 
of commercial kits in the international and nationals markets 
has given rise to this study. Moreover, uncontrolled experiments 
at laboratories specialized in autoimmunity have substantiated 
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HEp-2(2), followed by groups from Germany(16), France(15), 
Denmark(21) and Argentina(1).
Not only does this investigation demonstrate how the 
seventeen ANA-HEp-2 patterns on substrates from eight different 
origins were identified, but it also recommends that laboratories 
should use sample collections and include different cellular 
antigens whenever there is a change in HEp-2 slide batches or 
commercial brand.
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rESuMo 
Introdução: A imunofluorescência indireta (IFI) utilizando células HEp-2 como substrato antigênico é o teste padrão-ouro 
para a pesquisa de autoanticorpos contra antígenos celulares. Contudo, as condições de cultivo, fixação e permeabilização 
celular interferem diretamente na preservação e na distribuição espacial dos antígenos. Portanto, pode-se presumir que distintas 
condições no preparo das células possam interferir no reconhecimento dos padrões de imunofluorescência associados aos diversos 
autoanticorpos. Objetivo: Avaliar um painel de amostras de soro representativo de padrões nuclear, nucleolar, citoplasmático, de 
aparelho mitótico e de placa cromossômica em substratos de células HEp-2 de diferentes fornecedores. Materiais e métodos: Sete 
observadores blindados e independentes de três centros de referência avaliaram 17 amostras que apresentavam diferentes padrões 
nucleares, nucleolares, citoplasmáticos e associados ao aparelho mitótico em lâminas com células HEp-2 de oito procedências. As 
lâminas foram codificadas para manter a confidencialidade das marcas, bem como dos centros participantes. Resultados: Os 17 
padrões de imunofluorescência em células HEp-2 foram reconhecidos na maioria dos substratos. No entanto, alguns substratos 
mostraram déficit na apresentação de alguns padrões (nuclear pontilhado grosso/U1-ribonucleoprotein associado a anticorpos 
contra o RNP (U1 ribonucleoproteína), sugestivo da presença de anticorpos anti-CENP-F (proteína centromérica F), sugestivo de 
anticorpos contra antígenos de célula em proliferação (proliferating cell nuclear antigen [PCNA]), citoplasmático pontilhado fino 
associado a anticorpos anti-Jo-1 (histidil sintetase), anti-NuMA-1 (nuclear mitotic apparatus protein 1) e anti-NuMA-2 (nuclear mitotic 
apparatus protein 2). Conclusão: Em que pese a boa qualidade geral dos substratos avaliados, existe divergência nos resultados 
obtidos entre os diferentes substratos comerciais. As variações observadas podem ser devidas aos lotes avaliados, portanto não se 
pode generalizar para as respectivas marcas. Recomenda-se que cada novo lote ou marca de lâmina sejam testados com diferentes 
soros referência representativos dos diversos padrões.
  
Unitermos: anticorpos antinúcleo; fator antinúcleo; autoanticorpos; padrões de imunofluorescência; imunofluorescência indireta.
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Variability in the recognition of distinctive immunofluorescence patterns in different brands of HEp-2 cell slides
